Introduction {#s1}
============

Suicide is a major public health concern. About 35000 people die per year of suicide in the United States alone (Center for Disease Control, 2002; [@CIT0007], [@CIT0008]; [@CIT0003]; CDC, 2009). Significant progress has been made in understanding the neurobiology of suicide, primarily based on studies of postmortem brain samples. These studies suggested several abnormalities in the brain of suicide victims \[for review, see [@CIT0027] and [@CIT0018]\]. In a recent report, [@CIT0010] studied a genome-wide DNA methylation profiling in the postmortem brain from suicidal and nonsuicidal subjects and found that the DNA methylation scan identified an additive epigenetic and genetic association with suicide at rs720805 within the 3′untranslated region of the spindle and kinetochore associated complex subunit 2 (SKA2) gene in 3 brain cohorts. This finding was also replicated in blood from live cohorts. Whereas the major focus of this study was on SKA2 DNA methylation, they also studied the gene expression of SKA2 in suicide victims. They found that the gene expression of SKA2 in the postmortem brain of suicidal and nonsuicidal subjects was significantly reduced in suicidal subjects compared with controls. This study thus showed an abnormality of SKA2 gene in suicide pathogenesis. More recently, [@CIT0017] determined the expression of SKA2 in blood samples of suicidal patients and the postmortem brain of suicide victims. They observed decreased SKA2 gene expression in the blood of depressed patients and the brain of violent suicide completers. Studies of [@CIT0010] and [@CIT0017] thus strongly suggest dysregulation of SKA2 in suicide completers and its essential use as a blood marker for suicidality. It is not clear from their findings if decreased SKA2 gene expression in postmortem brain of suicide victims is independent of diagnosis (ie, whether suicide victims across all diagnostic groups have reduced SKA2 gene expression)---namely, if decreased SKA2 gene expression is specific for suicide and is not observed in the postmortem brain of nonsuicidal patients and if the protein expression of this gene is also altered in the postmortem brain of suicide victims.

To further extend the finding of decreased gene expression of SKA2 in suicide and to examine if this decrease is independent of psychiatric diagnosis and specific to suicide and is also associated with decreased protein expression, we have determined the mRNA and protein expression of SKA2 in the prefrontal cortex (PFC) obtained from suicide victims from different diagnostic groups, such as depression, schizophrenia, and other suicide groups (ie, substance abuse and/or conduct disorders) as well as from subjects from different diagnostic groups who died of natural causes (nonsuicidal patients) and from normal control subjects.

Methods {#s2}
=======

Subjects and Diagnoses {#s3}
----------------------

The study was performed in the PFC (Brodmann area 9) of 52 suicide victims (consisting of 24 depressed suicide victims, 16 schizophrenic suicide victims, and 12 other suicide victims with either substance abuse and/or conduct disorder), 27 nonsuicide patients (consisting of 12 depressed nonsuicide patients and 15 schizophrenic nonsuicidal patients), and 24 normal control subjects. Brain tissues were obtained from the Maryland Brain Collection at the Maryland Psychiatric Research Center, Baltimore, Maryland. All procedures were approved by the University of Maryland Institutional Review Board and by the University of Illinois Institutional Review Board.

Diagnostic Method {#s4}
-----------------

Subject diagnosis was based on the Structured Clinical Interview for DSM-IV ([@CIT0026]). At least one family member and/or a friend, after giving written informed consent, underwent an interview. Diagnoses were made by a consensus of 2 psychiatrists from the data obtained in this interview, medical records from the case, and records obtained from the Medical Examiner's office. Normal control subjects were verified as free from mental illnesses using these consensus diagnostic procedures.

Determination of mRNA Levels {#s5}
----------------------------

### RNA Extraction and Reverse Transcription {#s6}

Total RNA was extracted from 100mg of tissue using the TRIZOL reagent (Invitrogen) as per the manufacturer's instructions and treated with DNAse 1 (Invitrogen). The RNA yield was determined by absorbance at 260nm using NanoDrop ND-1000 (NanoDrop Technologies, Montchanin, DE). RNA quality was assessed using Agilent Bioanalyzer 2100 (Agilent). All samples had 28S/18S ratios \>1.2 and RNA integrity number \>6.6. The mean RNA integrity number was 7.2±0.6.

Expression levels of mRNA were determined using a 2-step real-time RT-PCR method. One microgram of total RNA was reverse transcribed using 50ng random hexamers, 2mM dNTP mix, 10 units ribonuclease inhibitor, and 200 units Moloney murine leukemia virus (MMLV)-reverse transcriptase enzyme in a final reaction volume of 20 μL.

### Relative Real-Time PCR {#s7}

Real-time PCR was performed using Pre-designed Taqman gene expression assays (Applied Biosystems, Foster City, CA) for all target and housekeeping genes on MX3005p sequence detection system (Agilent). The TaqMan assay IDs are in [Table 1](#T1){ref-type="table"}. To determine the stability and optimal number of housekeeping genes, we used geNORM version 3.4 (PrimerDesign) according to the manufacturer's instructions ([@CIT0028]) and tested 12 commonly used reference genes of different functional classes in 10 samples from each test group. The average gene-stability measure (M) ranked β-actin and GAPDH as the most stable genes in our samples. PCR efficiency was tested over 5-log dilution series and confirmed that β-actin, GAPDH, and SKA2 had similar amplification efficiencies. For each primer/probe set, the PCR reaction was carried out using 10 µL of cDNA diluted 1:10-fold. Each quantitative PCR plate included a "no reverse transcriptase" and "no template" control to eliminate nonspecific amplification, one sample was run on a gel to confirm specificity, and samples were run in triplicates. Target gene quantitative PCR data was normalized to the geometic mean of β-actin and GAPDH and was expressed relative to the control samples using 2^−(ΔΔ*Ct*)^ method.

###### 

Taqman Primers/Probes Used for qPCR Analysis

          **Taqman Accession**   **Probe Location (Exon Boundary**)   **Assay Function**
  ------- ---------------------- ------------------------------------ --------------------
  ACTB    Hs99999903_m1          1-1                                  Housekeeping (HK)
  GAPDH   Hs99999905_m1          3-3                                  HK
  SKA2    Hs00735057_m1          3--4                                 Target gene

Determination of Protein Expression of SKA2 by Western Blot {#s8}
-----------------------------------------------------------

Gel electrophoresis and immunolabeling of SKA2 proteins were performed by Western blot as previously reported ([@CIT0006]). Equal amounts of protein samples (20 μg protein in each lane) obtained from membrane fraction were loaded onto 7.5% (w/v) acrylamide gel and subsequently transferred electrophoretically to enhanced chemiluminescent (ECL) nitrocellulose membranes (Amersham Pharmacia, Piscataway, NJ). The blots were incubated overnight at 4°C with primary antibody for SKA2 (Santa Cruz Biotechnology, Inc., catalog no. sc-136868) at a dilution of 1:3000 and with horseradish-peroxidase-linked secondary anti-rabbit antibody at a dilution of 1:3000 (Amersham Pharmacia) for 3 to 5 hours at room temperature. The signals were detected with the ECL Western-blot detection system (Amersham) followed by exposure to ECL-autoradiographic film (Amersham). The membranes were stripped using stripping solution (Chemicon International, Temecula, CA) and probed with β-actin monoclonal primary (1:5000 for 2 hours; Sigma Chemical Co., St. Louis, MO) and anti-mouse secondary antibody (1:5000 for 2 hours). The bands on the autoradiograms were quantified using the Loats Image Analysis System (Westminister, MD). A ratio of the optical density of SKA2 over the optical density of the corresponding β-actin band was calculated.

Before starting the experiment, immunolabeling of SKA2 proteins was characterized ([Figure 1](#F1){ref-type="fig"}). The specificity of SKA2 proteins was checked by running NIH3T3 cells and E431 immune lines along with membrane fraction of PFC from one control subject. It was observed that extracts from different cell lines as well as membrane fraction migrated to 18kDa ([Figure 1](#F1){ref-type="fig"}). The appropriate concentration of proteins was selected by running 5 different concentrations (5--80 μg) of protein from membrane fraction of PFC. The optical density was linear between these concentrations of protein. We therefore used 20 μg of protein in subsequent experiments. Similarly, the antibody concentration and duration of exposure of the nitrocellulose membrane onto autoradiographic film were also characterized.

![The specificity of spindle and kinetochore associated complex subunit 2 (SKA2) proteins was checked by running NIH3T3 cells and E431 immune lines along with membrane fraction of prefrontal cortext (PFC) from one control subject. Extracts from different cell lines as well as membrane fraction migrated to 18kDa.](ijnppy_pyw015_f0001){#F1}

Statistical Analysis and Effect of Confounding Variables {#s9}
--------------------------------------------------------

The data analyses were performed using the SAS 9.2 statistical software package. Data normality was assessed by Shapiro-Wilk test, and all analyses were 2-tailed with a level of significance of *P*\<.05. Linear regression was performed to compare the effects of 3 groups: normal control subjects, suicide victims, and nonsuicidal subjects for outcome measures of SKA2 on protein and gene expression by adjusting the effects of age, gender, postmortem interval (PMI), and brain pH. For multiple comparisons, we used *t* tests with Bonferroni correction to adjust the type I error rates. We also performed posthoc *t* tests for pairwise comparisons.

To examine if the observed decrease in SKA2 expression in the PFC of suicide victims is related to the covariates, we examined the effects of age, gender, PMI, and brain pH on these parameters. There was no significant effect of age, gender, PMI, or brain pH on the protein or mRNA expression levels of SKA2 in any of the diagnostic groups.

Results {#s10}
=======

The demographic and clinical characteristics of normal controls, suicide victims, and nonsuicidal patients are shown in [Table 2](#T2){ref-type="table"}. Although the groups were well matched, there were some significant differences. There was a significant difference in age between normal controls with schizophrenic suicide (*P*=.05). There was a significant difference in PMI between normal controls and other suicide group (*P* \<.01). There were significant differences in brain pH between normal controls vs schizophrenic suicide (*P* \<.01), vs other suicide (*P* \<.01), vs depressed nonsuicide (*P* \<.01), and vs schizophrenic nonsuicide (*P* \<.01) groups. However, these variables were used as covariates when analyzing the protein and mRNA expression of SKA2 in these groups.

###### 

Demographic Characteristics of Subjects

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    **Group**              **Age (y**)   **Race**   **Gender**   **PMI (h**)   **Brain**\   **Cause of Death**                                            **Psychotropic Drugs**\                              **Psychiatric Diagnosis**
                                                                                                                               **pH**                                                                     **(at Time of Death)**                               
  ------------------------------------------------- ---------------------- ------------- ---------- ------------ ------------- ------------ ------------------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------
  **Normal Control Subjects** ^***a***^                                                                                                                                                                                                                        

  1\.                                               CONTROL                19            Black      Male         11            6.9          GSW                                                           None                                                 Normal

  2\.                                               CONTROL                22            Black      Male         19            6.9          GSW                                                           None                                                 Normal

  3\.                                               CONTROL                42            White      Female       23            7.2          Pneumonia                                                     None                                                 Normal

  4\.                                               CONTROL                37            Black      Male         5             7.1          ASCVD                                                         None                                                 Normal

  5\.                                               CONTROL                31            Black      Male         8             7.2          GSW                                                           None                                                 Normal

  6\.                                               CONTROL                46            Black      Male         9             7.1          Multiple injuries                                             None                                                 Normal

  7\.                                               CONTROL                33            White      Male         15            7.0          GSW                                                           None                                                 Normal

  8\.                                               CONTROL                48            White      Male         26            6.9          ASCVD                                                         None                                                 Normal

  9\.                                               CONTROL                40            White      Female       7             7.0          ASCVD                                                         None                                                 Normal

  10\.                                              CONTROL                23            Black      Male         15            6.8          GSW                                                           None                                                 Normal

  11\.                                              CONTROL                83            White      Male         20            7.1          ASCVD                                                         None                                                 Normal

  12\.                                              CONTROL                65            Black      Female       23            6.9          ASCVD                                                         None                                                 Normal

  13\.                                              CONTROL                35            White      Male         24            6.9          Crush injury to abdomen and chest                             None                                                 Normal

  14\.                                              CONTROL                52            White      Male         30            7.3          ASCVD                                                         None                                                 Normal

  15\.                                              CONTROL                37            White      Male         24            7.0          ASCVD                                                         None                                                 Normal

  16\.                                              CONTROL                45            White      Male         22            7.3          ASCVD                                                         None                                                 Normal

  17\.                                              CONTROL                26            White      Male         12            6.9          Arrhythmia                                                    None                                                 Normal

  18\.                                              CONTROL                47            White      Male         10            7.0          ASCVD                                                         None                                                 Normal

  19\.                                              CONTROL                31            White      Male         16            7.2          MVA                                                           None                                                 Normal

  20\.                                              CONTROL                60            White      Male         15            7.1          Accidental drowning                                           None                                                 Normal

  21\.                                              CONTROL                28            White      Male         13            6.8          Electrocution                                                 None                                                 Normal

  22\.                                              CONTROL                45            White      Female       16            6.9          Cardiac arrhythmia                                            None                                                 Normal

  23\.                                              CONTROL                62            White      Male         19            7.0          Cardiac arrest                                                None                                                 Normal

  24\.                                              CONTROL                53            White      Male         15            6.9          ASCVD                                                         None                                                 Normal

  **Depressed Suicide Victims** ^***b***^                                                                                                                                                                                                                      

  1\.                                               SUICIDE                27            White      Male         24            7.0          GSW                                                           None                                                 MDD, ethanol abuse

  2\.                                               SUICIDE                44            White      Female       11            7.2          Drug overdose                                                 Nortriptyline                                        MDD, ethanol abuse

  3\.                                               SUICIDE                36            White      Female       10            7.1          GSW                                                           None                                                 MDD

  4\.                                               SUICIDE                24            White      Male         7             7.1          GSW                                                           Ethanol                                              MDD

  5\.                                               SUICIDE                43            White      Male         12            7.0          Drug Overdose                                                 None                                                 MDD, polysubstance abuse

  6\.                                               SUICIDE                53            White      Male         23            6.9          Jumped from height                                            None                                                 MDD

  7\.                                               SUICIDE                41            White      Female       27            7.1          Drug Overdose                                                 Amitriptyline, desipramine, nortriptyline, ethanol   MDD, ethanol abuse

  8\.                                               SUICIDE                22            Black      Female       16            7.3          Drug overdose                                                 None                                                 MDD

  9\.                                               SUICIDE                46            White      Female       21            6.9          Drug overdose                                                 Amitriptyline, desipramine, ethanol                  MDD

  10\.                                              SUICIDE                36            White      Female       18            7.2          GSW                                                           None                                                 MDD

  11\.                                              SUICIDE                38            White      Male         24            7.0          Drug overdose & Ethanol overdose                              Ethanol                                              MDD, ethanol abuse

  12\.                                              SUICIDE                46            White      Female       16            6.8          Drug overdose /\                                              Nortriptyline                                        MDD, panic disorder with agoraphobia
                                                                                                                                            Nortryptyline Intoxication                                                                                         

  13\.                                              SUICIDE                23            White      Male         12            7.0          Hanging                                                       Paroxetine                                           MDD

  14\.                                              SUICIDE                18            White      Male         17            6.3          Hanging                                                       None                                                 MDD

  15\.                                              SUICIDE                30            White      Male         17            7.1          Hanging                                                       Venlafaxine                                          MDD

  16\.                                              SUICIDE                19            White      Male         18            6.2          CO intoxication                                               Ethanol, CO                                          MDD, ethanol abuse, polysubstance abuse

  17\.                                              SUICIDE                44            White      Female       30            7.2          Drug overdose, Ethanol intoxication                           Fluoxetine, ethanol                                  MDD, ethanol abuse, opioid abuse

  18\.                                              SUICIDE                74            White      Female       27            7.0          Venlafaxine overdose                                          Venlafaxine, ethanol                                 MDD, ethanol abuse

  19\.                                              SUICIDE                25            White      Male         14            6.8          Hanging                                                       Ethanol                                              MDD

  20\.                                              SUICIDE                23            Black      Male         23            6.9          Hanging                                                       None                                                 MDD

  21\.                                              SUICIDE                63            White      Male         19            6.9          Drug overdose, Ethanol intoxication                           Ethanol                                              MDD

  22\.                                              SUICIDE                67            White      Male         22            7.0          GSW                                                           Fluoxetine, venlafaxine                              MDD

  23\.                                              SUICIDE                40            White      Female       20            7.0          Drug overdose                                                 Alprazolam                                           MDD

  24\.                                              SUICIDE                53            White      Male         26            7.1          Suicide by stab wound                                         Sertraline                                           MDD

  **Schizophrenia Suicide Victims** ^***c***^                                                                                                                                                                                                                  

  1\.                                               SUICIDE                45            Black      Male         10            6.8          Suicide, stab wound                                           Haloperidol                                          Schizophrenia

  2\.                                               SUICIDE                20            White      Female       11            6.5          Jump from height, multiple injuries                           Haloperidol                                          Schizophrenia

  3\.                                               SUICIDE                54            White      Male         12            6.6          Suicide, drowning                                             Haloperidol                                          Schizophrenia

  4\.                                               SUICIDE                20            White      Male         23            6.4          Drug overdose                                                 Fluphenazine                                         Schizophrenia, ethanol abuse

  5\.                                               SUICIDE                40            White      Male         17            6.8          Jump from height, multiple injuries                           Trifluoperazine                                      Schizophrenia

  6\.                                               SUICIDE                28            White      Male         13            7.1          Suicide, hanging                                              Thioridazine                                         Schizophrenia, ethanol abuse

  7\.                                               SUICIDE                35            White      Female       7             6.9          Suicide, multiple drugs intoxication                          Amitriptyline, amoxapine, loxapine, nortriptyline    Schizophrenia

  8\.                                               SUICIDE                37            White      Male         20            6.7          Suicide, drowning                                             Haldol                                               Schizophrenia, ethanol abuse

  9\.                                               SUICIDE                37            White      Male         22            7.1          Suicide, GSW to chest                                         None                                                 Schizophrenia, ethanol abuse

  10\.                                              SUICIDE                51            White      Female       21            6.5          Suicide, overdose                                             None                                                 Schizophrenia

  11\.                                              SUICIDE                34            White      Male         16            6.60         Suicide, jumped from height, multiple injuries                Mesoridazine                                         Schizophrenia

  12\.                                              SUICIDE                21            White      Male         26            6.4          Jumped from height, multiple injuries                         Fluphenazine                                         Schizophrenia

  13\.                                              SUICIDE                23            White      Male         20            6.6          Jumped from height, multiple injuries                         None                                                 Schizophrenia, hallucinogen abuse

  14\.                                              SUICIDE                45            Black      Male         8             6.6          Suicide, hanging                                              Olanzapine                                           Schizophrenia

  15\.                                              SUICIDE                37            White      Male         14            6.7          Suicide, electrocution                                        Risperidone, fluphenazine                            Schizophrenia

  16\.                                              SUICIDE                54            White      Male         19            6.6          Suicide, bleeding                                             None                                                 Schizophrenia

  **Other Suicide Victims** ^***d***^                                                                                                                                                                                                                          

  1\.                                               SUICIDE                34            White      Male         16            6.4          GSW                                                           Ethanol                                              Ethanol abuse

  2\.                                               SUICIDE                21            White      Male         17            6.8          GSW                                                           None                                                 Adjustment disorder, mixed

  3\.                                               SUICIDE                75            White      Male         18            6.4          GSW                                                           None                                                 Adjustment disorder, conduct disorder

  4\.                                               SUICIDE                87            White      Male         16            6.6          GSW                                                           None                                                 Adjustment disorder, conduct disorder

  5\.                                               SUICIDE                39            White      Male         30            6.7          Asphyxia                                                      Freon, cocaine, and metabolites                      Cocaine abuse

  6\.                                               SUICIDE                30            White      Male         32            6.5          Hanging                                                       Cocaine, ethanol                                     Ethanol abuse, cocaine abuse, drug abuse

  7\.                                               SUICIDE                40            White      Male         26            6.7          GSW                                                           Ethanol                                              Adjustment disorder

  8\.                                               SUICIDE                20            White      Male         32            6.9          Hanging                                                       Ethanol                                              Ethanol abuse

  9\.                                               SUICIDE                71            White      Female       24            6.5          Drug overdose                                                 None                                                 Adjustment disorder, mixed

  10\.                                              SUICIDE                24            White      Male         22            6.8          Hanging                                                       None                                                 Schizoaffective disorder

  11\.                                              SUICIDE                21            White      Male         23            6.8          Hanging                                                       None                                                 Adjustment disorder, conduct disorder

  12\.                                              SUICID                 19            White      Male         15            6.9          GSW to chest                                                  Fluoxetine                                           Dissociative disorder, substance abuse, PTSD

  **Depressed Nonsuicide Subjects** ^***e***^                                                                                                                                                                                                                  

  1\.                                               Nonsuicide depressed   65            White      Male         14            6.9          ASCVD                                                         None                                                 MDD

  2\.                                               Nonsuicide depressed   55            Black      Female       8             6.4          ASCVD                                                         Fluoxetine, ethanol                                  MDD, polysubstance abuse

  3\.                                               Nonsuicide depressed   71            White      Male         4             6.3          ASCVD                                                         Bupropion                                            MDD

  4\.                                               Nonsuicide depressed   74            Black      Female       7             6.7          ASCVD                                                         Paroxetine, thioridazine                             MDD

  5\.                                               Nonsuicide depressed   14            White      Male         11            7.0          MVA                                                           Sertraline                                           MDD, polysubstance abuse

  6\.                                               Nonsuicide depressed   39            White      Male         36            6.8          Fatty Liver                                                   Thioridazine                                         MDD

  7\.                                               Nonsuicide depressed   46            Black      Male         20            7.1          Seizure d/o                                                   Fluoxetine, risperidone                              MDD

  8\.                                               Nonsuicide depressed   59            White      Male         20            7.0          ASCVD                                                         Sertraline                                           MDD, ethanol dependence

  9\.                                               Nonsuicide depressed   46            White      Female       23            6.9          Mixed Drug intoxication                                       Bupropion, lamotrigine                               MDD, ethanol abuse, polysubstance abuse

  10\.                                              Nonsuicide depressed   29            White      Female       22            6.9          Obesity,\                                                     Fluoxetine, norfluoxetine                            MDD
                                                                                                                                            Cardiomegaly                                                                                                       

  11\.                                              Nonsuicide depressed   49            White      Male         24            7.1          ASCVD                                                         Desmethylsertraline                                  MDD

  12\.                                              Nonsuicide depressed   47            White      Female       26            6.5          Diabetic ketoacidosis                                         Fluoxetine                                           MDD

  **Schizophrenia Nonsuicide Subjects** ^***f***^                                                                                                                                                                                                              

  1\.                                               Nonsuicide             71            White      Female       12            6.8          ASCVD                                                         None                                                 Schizophrenia

  2\.                                               Nonsuicide             41            Black      Female       16            6.6          Morbidly obese, dilated cardiomyopathy                        Perphenazine                                         Schizophrenia

  3\.                                               Nonsuicide             50            Black      Female       11            6.9          Environmental hyperthermia, complication from schizophrenia   None                                                 Schizophrenia

  4\.                                               Nonsuicide             24            Black      Male         23            6.7          ASCVD                                                         Olanzapine                                           Schizophrenia

  5\.                                               Nonsuicide             77            White      Male         17            6.8          ASCVD                                                         Risperidone                                          Schizophrenia

  6\.                                               Nonsuicide             45            Black      Female       17            6.6          Diabetic ketoacidosis                                         Haloperidol                                          Schizophrenia

  7\.                                               Nonsuicide             47            Black      Male         20            7.0          ASCVD                                                         Fluphenazine                                         Schizophrenia, ethanol abuse, polysubstance abuse

  8\.                                               Nonsuicide             55            White      Male         12            6.4          ASCVD                                                         Olanzapine                                           Schizophrenia, ethanol abuse

  9\.                                               Nonsuicide             41            Black      Male         19            6.5          ASCVD                                                         Haloperidol                                          Schizophrenia, ethanol abuse

  10\.                                              Nonsuicide             40            White      Male         14            6.6          MVA                                                           None                                                 Schizophrenia, ethanol abuse, cannabis abuse, cocaine abuse

  11\.                                              Nonsuicide             33            Black      Male         12            6.2          Appendicitis/ Peritonitis                                     Olanzapine                                           Schizophrenia

  12\.                                              Nonsuicide             42            White      Female       14            6.8          Liver Cirrhosis                                               None                                                 Schizophrenia, cocaine abuse, polysubstance abuse

  13\.                                              Nonsuicide             53            White      Male         14            6.1          ASCVD                                                         None                                                 Schizophrenia

  14\.                                              Nonsuicide             83            White      Male         18            7.0          Electrocution, accidental                                     None                                                 Schizophrenia

  15\.                                              Nonsuicide             57            White      Male         11            6.2          Allergic reaction                                             Haloperidol                                          Schizophrenia
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CO, carbon monoxide; GSW, gunshot wound; MDD, major depressive disorder; MVA, motor vehicle accident.

^*a*^ Normal controls (mean ± SD) age is 42.08±15.35 years; PMI is 16.54±6.56 hours; brain pH is 7.02±0.15; 7 Black, 17 White; 20 Males, 4 Females.

^*b*^ Depressed suicide victims (mean ± SD) age is 38.96±15.40 years; PMI is 18.92±6.02 hours; brain pH is 6.96±0.25; 2 Black, 22 White; 14 Males, 10 Females.

^*c*^ Schizophrenia suicide victims (mean ± SD) age is 36.31±11.63 years; PMI is 16.19±5.69 hours; brain pH is 6.68±0.21; 2 Black, 14 White; 13 Males, 3 Females.

^*d*^ Other suicide victims (mean ± SD) age is 40.08±24.03 years; PMI is 22.58±6.35 hours; brain pH is 6.67±0.18; 12 White; 11 Males, 1 Females.

^*e*^ Depressed nonsuicide subjects (mean ± SD) age is 49.50±17.18 years; PMI is 17.92±9.32 hours; brain pH is 6.80±0.27; 3 Black, 9 White; 7 Males, 5 Females.

^f^ Schizophrenia nonsuicide subjects (mean ± SD) age is 50.60±16.17 years; PMI is 15.33±3.62 hours; brain pH is 6.61±0.29; 7 Black, 8 White; 10 Males, 5 Females.

mRNA Expression of SKA2 in Normal Control Subjects, Suicide Victims, and Nonsuicidal Patients {#s11}
---------------------------------------------------------------------------------------------

We determined the mRNA expression of SKA2 in the PFC (Brodmann area 9) of 24 normal control subjects, 52 suicide victims with different diagnoses, and 27 nonsuicidal subjects. The mean mRNA expression of SKA2 in these 3 groups is shown in [Figure 2A](#F2){ref-type="fig"}. One-way ANOVA showed significant differences between the groups (F= 6447.06, *P* \<.001), and when we compared the mRNA expression of SKA2 between these 3 groups, we found that the mRNA expression of SKA2 was significantly decreased \[t= -5.40, *P* \<.001, CI (-.99,-.37), ES = .58\] in suicide victims compared with normal control subjects ([Figure 2A](#F2){ref-type="fig"}). The SKA2 expression in suicide victims was also significantly decreased (t=-5.70, *P* \<.001, ES =. 58) in the PFC of suicide victims compared with nonsuicidal patients ([Figure 2A](#F2){ref-type="fig"}). When we compared the SKA2 expression between nonsuicidal patients and normal control subjects, we found that there was no significant difference (t=-.256, *P* =1.0, ES = .04) in the expression of SKA2 between normal control subjects and nonsuicidal patients ([Figure 2A](#F2){ref-type="fig"}). These results suggested that decreased SKA2 expression was specific to suicide.

![Mean mRNA expression levels of spindle and kinetochore associated complex subunit 2 (SKA2) in the prefrontal cortext (PFC) of normal controls, suicide victims, and nonsuicidal subjects from different diagnostic groups. The data are shown as fold change in mRNA levels and values are fold change ± SEM. (A) Mean mRNA expression levels of SKA2 in normal controls, all suicide victims, and all nonsuicidal patients. (a) Normal controls vs all suicides: *P*\< .0001. (b) All nonsuicidal vs all suicides: *P*\< .0001. (B) Mean mRNA expression levels of SKA2 in normal controls, depressed suicide victims, nonsuicidal depressed subjects, schizophrenic suicide victims, nonsuicidal schizophrenic subjects, and other (mainly substance abuse and/or conduct disorders) suicide victims. \**P* \< .05.](ijnppy_pyw015_f0002){#F2}

To examine the diagnostic specificity, that is, if decreased mRNA expression of SKA2 in suicide victims was independent of diagnosis, we divided the suicide victims into different diagnostic groups. The suicide group consisted of 24 depressed suicide victims, 16 schizophrenic suicide victims, and 12 suicide victims with other diagnoses, primarily substance abuse and/or conduct disorders. We found that mean mRNA expression of SKA2 in depressed suicide victims (t = 5.94, *P* \<.001, ES = .66), schizophrenic suicide victims (t = 2.23, *P* \<.03, ES = .37), and other suicide victims (t = 4.52, *P* \<.001, ES = .58) was significantly different compared with normal control subjects, as shown in [Figure 2B](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}. However, there was no significant difference between the 3 suicide groups compared against each other ([Table 3](#T3){ref-type="table"}).

###### 

Statistical Summary for mRNA Expression of SKA2

  ---------------------------------------------------------------------------------------
  **Comparisons**     **T STAT**                 ***P* value**   **Effect Size**   
  ------------------- -------------------------- --------------- ----------------- ------
  Normal controls     Depressed suicide          -5.949763       \<.0001           -.66

  Normal controls     Other suicide              -4.52416        .0001             -.58

  Normal controls     Schizophrenic suicide      -2.23897        0.3               -.37

  Normal controls     Depressed\                 0.462002        1.0000            .07
                      nonsuicide                                                   

  Normal controls     Schizophrenic nonsuicide   0.760534        1.0000            .15

  Depressed suicide   Other suicide              0.686473        1.0000            .104

  Depressed suicide   Schizophrenic suicide      3.043836        .0196             .48

  Other suicide       Schizophrenic suicide      2.111131        .2297             .37

  Depressed\          Schizophrenic nonsuicide   1.037718        .9148             .20
  nonsuicide                                                                       
  ---------------------------------------------------------------------------------------

On the other hand, the SKA2 mRNA expression was not significantly different in nonsuicidal depressed subjects and nonsuicidal schizophrenic subjects compared with normal control subjects ([Figure 2B](#F2){ref-type="fig"}; [Table 3](#T3){ref-type="table"}), showing that decreased SKA2 mRNA expression was specific to suicide and independent of diagnosis.

We also compared the mRNA expression of SKA2 between depressed suicide victims and nonsuicidal depressed subjects and between schizophrenic suicide victims and nonsuicidal schizophrenic subjects ([Table 3](#T3){ref-type="table"}). We found that the mRNA expression of SKA2 was again significantly lower (t = -3.68, *P* =.009, ES = .56) in depressed suicide victims compared with nonsuicidal depressed subjects, and it was also significantly lower in schizophrenic suicide victims compared with nonsuicidal schizophrenic subjects (t = -3.61, *P* =.0012, ES = .57) ([Figure 2B](#F2){ref-type="fig"}; [Table 3](#T3){ref-type="table"}).

Protein Expression of SKA2 in Normal Controls, Suicide Victims, and Nonsuicidal Patients {#s12}
----------------------------------------------------------------------------------------

Representative immunoblots of 2 subjects from the following groups---normal controls, depressed suicide, nonsuicidal depressed, schizophrenic suicide, nonsuicidal schizophrenic, and other suicide---are shown in the [Figure 3](#F3){ref-type="fig"}. As can be seen, SKA2 protein expression appears to be decreased in suicide (ie, depressed suicide, schizophrenic suicide, and other suicide) victims, but not in nonsuicidal (ie, nonsuicidal depressed and nonsuicidal schizophrenic) subjects compared with normal control subjects.

![Representative Western blots showing the immunolabeling of spindle and kinetochore associated complex subunit 2 (SKA2) and beta-actin in the prefrontal cortex (PFC) membrane fraction of 2 subjects from the following groups: normal controls, depressed suicide, nonsuicidal depressed, schizophrenic suicide, nonsuicidal schizophrenic, and other suicide (consisting mainly of substance abuse and/or conduct disorders).](ijnppy_pyw015_f0003){#F3}

The mean protein expression of SKA2 in suicide victims, nonsuicidal subjects, and normal controls are shown in [Figure 4A](#F4){ref-type="fig"}. We examined if protein expression of SKA2, similar to its mRNA expression, was also altered in the PFC of suicide victims by comparing SKA2 protein expression between suicide victims, nonsuicidal subjects, and normal controls. The regression analysis showed differences between normal controls, total suicide victims, and total nonsuicidal subjects (F = 460.1, *P* \<.0001). We then examined if there was a significant difference between the groups by posthoc *t* test with Bonferroni correction. We found that the protein expression of SKA2 was significantly decreased in suicide victims (t = 3.98, *P* =.0004, ES = .46) compared with normal control subjects and nonsuicidal patients ([Figure 4A](#F4){ref-type="fig"}). We also found that there was no significant difference (t =1.10, *P* =.82, ES = .15) in the protein expression levels of nonsuicidal patients compared with normal control subjects.

![Protein expression levels of spindle and kinetochore associated complex subunit 2 (SKA2) in the prefrontal cortext (PFC) of normal controls, and suicide victims and nonsuicidal subjects from different diagnostic groups. The data are shown as percent of controls. Values are mean ± SD. (A) Mean protein expression levels of SKA2 in normal controls, depressed suicide victims, nonsuicidal depressed subjects, schizophrenic suicide victims, nonsuicidal schizophrenic subjects, and other (mainly substance abuse and/or conduct disorders) suicide victims. (a) Normal controls vs all suicides: *P* \< .001. (b) All nonsuicidal vs all suicides: *P* \< .05. (B)\
Mean protein expression levels of SKA2 in normal controls, depressed suicide victims, nonsuicidal depressed subjects, schizophrenic suicide victims, nonsuicidal schizophrenic subjects, and other (mainly substance abuse and/or conduct disorders) suicide victims. \**P* \< .05.](ijnppy_pyw015_f0004){#F4}

To examine if SKA2 protein expression was related to diagnosis or was independent of diagnosis and specific to suicide, we compared each diagnostic group separately with each other and also with normal control subjects as well as with each diagnostic group in the nonsuicidal patient group ([Table 4](#T4){ref-type="table"}). Suicide groups consisted of depressed suicide victims (n = 24), schizophrenic suicide victims (n=16), and other suicide victims (n=12), consisting primarily the subjects with substance abuse and/or conduct disorders.

###### 

Statistical Summary for Protein Expression of SKA2

  ----------------------------------------------------------------------------------------
  **Comparisons**     **T STAT**                 ***P* value**   **Effect Size**   
  ------------------- -------------------------- --------------- ----------------- -------
  Normal controls     Depressed suicide          3.67543         .0028             .47

  Normal controls     Other suicide              3.144044        .0148             .51

  Normal controls     Schizophrenic suicide      2.275038        .3                .37

  Normal controls     Depressed\                 -2.40996        .0603             -.39
                      nonsuicide                                                   

  Normal controls     Schizophrenic nonsuicide   -0.4643         1.0000            -.08

  Depressed suicide   Other suicide              -0.00612        1.0000            -.001

  Depressed suicide   Schizophrenic suicide      -0.86157        1.0000            -.14

  Other suicide       Schizophrenic suicide      -0.76296        1.0000            -.15

  Depressed\          Schizophrenic nonsuicide   -2.48918        .0497             -.45
  nonsuicide                                                                       
  ----------------------------------------------------------------------------------------

The mean protein expression of SKA2 in each group is shown in [Figure 4B](#F4){ref-type="fig"}. When we compared different groups against the normal controls, we found that the protein expression of SKA2 in depressed suicide (t = 3.67, *P* =.003, ES = .47), schizophrenic suicide (t = 2.27, *P* \<.03, ES=.37), and other suicide groups (t = 3.14, *P* =.01, ES = .51) was significantly decreased compared with normal control subjects ([Figure 4B](#F4){ref-type="fig"}; [Table 4](#T4){ref-type="table"}).There was no significant difference between any of the suicide groups compared against each other. When we compared the SKA2 protein expression in nonsuicidal subjects, consisting of 12 nonsuicidal depressed (t = 2.41, *P* =.06, ES = .38) and 15 nonsuicidal schizophrenic subjects (t = -.46, *P* =1.0, ES = .07), we found that the mean SKA2 protein expression in these subjects was not significantly different from that of the normal control subjects ([Figure 4B](#F4){ref-type="fig"}; [Table 4](#T4){ref-type="table"}). These results therefore suggested that decreased SKA2 protein expression in suicide is independent of psychiatric diagnosis, since suicide victims from different diagnostic groups still showed a significant decrease in SKA2 protein expression, whereas nonsuicidal subjects did not show any significant difference compared with normal control subjects. These results also suggested that decreased SKA2 protein expression was specific to suicide.

Discussion {#s13}
==========

In this study, we found that the gene and protein expression of SKA2, a gene recently implicated in suicidal behavior ([@CIT0010]), is significantly decreased in the PFC of suicide victims compared with normal controls. The protein and gene expression of SKA2 in the PFC of nonsuicidal patients was not significantly different from normal controls. Also, the gene and protein expression of SKA2 in the PFC was significantly lower in suicide victims compared with nonsuicidal patients. This observation suggests that decreased protein and mRNA expression of SKA2 is specific to suicide, as this decrease was not observed in nonsuicidal subjects.

We then examined if the decrease of SKA2 in the PFC of suicide victims is independent of diagnosis. We observed that SKA2 protein and gene expression was decreased in depressed suicide, schizophrenic suicide, and other suicide groups compared with normal controls and also compared with corresponding nonsuicidal groups, for example, depressed suicide vs depressed nonsuicide, suggesting that decreased SKA2 expression is not related to diagnosis (ie, it is independent of diagnosis, since the decrease was observed only in suicide victims).

In a recent study, [@CIT0010] reported altered DNA methylation of SKA2 in the blood of suicide patients and the brain of suicide victims. They also found decreased mRNA SKA2 expression in the PFC of suicide victims. However, it was not clear if the observed decrease in SKA2 mRNA expression was independent of diagnosis.

Our observation that mRNA expression of SKA2 is decreased in the PFC of suicide victims compared with controls is similar to that of [@CIT0010]. Although the studies of [@CIT0010] focused more on DNA methylation in the brain and also in the blood, we focused on SKA2 abnormalities in suicide brain. In addition to mRNA expression, we have determined SKA2 protein expression in our cohort, and we also examined the diagnostic specificity of decreased SKA2 expression by determining SKA2 in suicide victims and nonsuicidal psychiatric subjects belonging to different diagnostic groups. We examined if decreased SKA2 expression was specific to suicide and not related to diagnosis. Our results suggest decreased gene and protein expression of SKA2 in suicide. The reasons, mechanisms, or functional consequences of this decrease are unclear, since the role of SKA2 in suicide and psychiatric disorders is not well known.

In a more recent study, [@CIT0017] found decreased SKA2 gene expression in violent suicide completers. We therefore also compared SKA2 expression between violent and nonviolent suicide. Although the number of violent suicide completers was small, we did not find differences in SKA2 protein or mRNA expression between violent and nonviolent suicide completers.

SKA2 belongs to the SKA complex consisting of the proteins SKA1 and SKA2 ([@CIT0011]). This complex was originally identified in a proteomic survey of the human mitotic spindle apparatus ([@CIT0011]). A novel spindle and kinetochore associated (SKA) complex required for a timely anaphase onset consists of both SKA1 and SKA2. A third component of the SKA complex, known as SKA3, has also been identified ([@CIT0023]), and the depletion of this gene (*SKA3*) from the complex results in mitotic arrest ([@CIT0009]; [@CIT0029]). It is believed that this complex is required to generate stable kinetochore-microtubule attachments during mitosis in humans ([@CIT0011]).

This SKA complex in general, and SKA2 in particular, may be associated with suicide/suicidal behavior through its interaction with glucocorticoid receptor (GR), which is involved in the feedback inhibition of hypothalamic-pituitary-adrenal (HPA) axis ([@CIT0021]; [@CIT0025]). Abnormal HPA axis function has been implicated in depression and completed suicide ([@CIT0005]). One of the tests by which HPA axis abnormalities have been assessed is the dexamethasone (DEX) suppression test (DST). DST was found to be abnormal in both depression and suicidal behavior ([@CIT0022]; [@CIT0005]; [@CIT0021]). In addition, some studies suggest that abnormal DST may be a risk factor and even a predictor of completed suicide ([@CIT0005]; [@CIT0030]; [@CIT0012]). For example, [@CIT0030] found that DST nonsuppressors were significantly more likely to commit and complete suicide than DST suppressors. Other investigators have also found an association between DST nonsuppression and suicide ([@CIT0005]; [@CIT0030]; [@CIT0012]; [@CIT0014]).

The DST nonsuppression (ie, abnormal DST) or the HPA axis hyperactivity in depressed and suicidal patients has been related to a deficiency in feedback mechanisms, primarily to altered GR in the brain ([@CIT0016]; [@CIT0021]). Thus, GR is a key component regulating the HPA axis and it may be abnormal in suicide. Abnormality of this receptor in the postmortem brain has been implicated in suicide ([@CIT0015]; [@CIT0001]; [@CIT0020]). For example, it has been found that the expression of GR and its target gene, GILZ, is decreased in the PFC and amygdala of suicide victims ([@CIT0001]; [@CIT0020]). Abnormalities of DNA methylation of GR have also been reported in suicide subjects with early life trauma ([@CIT0015]). Thus, it is quite possible that abnormal DST suppression and GR expression observed in suicide ([@CIT0024]; [@CIT0001]; [@CIT0020]) may be related to a functional interaction between GR and SKA2, as suggested by some studies ([@CIT0025]). [@CIT0025] studied in great detail the interaction of SKA2 with GR and found that SKA2 is colocalized with GR in the cytoplasm and moves to the nucleus in DEX-treated cells. They also found that in cells overexpressing a GR DNA construct, there was a partial translocation of SKA2 to the nucleus following glucocorticoid treatment. Since SKA2 has no nuclear localization, it may interact with GR in the cytoplasm to facilitate its movement to the nucleus. The main requirement for this process to occur is the overexpression of GR. Since there is some evidence to suggest that GR may be underexpressed in suicide brain ([@CIT0001]; [@CIT0020]), this may lead to decreased SKA2 translocation to the nucleus. Similarly, underexpression of SKA2 in suicide may alter the translocation of GR to the nucleus ([@CIT0025]).

Another possible mechanism of GR-SKA2 interaction may be the SKA2 effect on GR transactivation function. [@CIT0025] found that overexpression of SKA2 results in modest enhancement of GR transactivation, while knockdown of SKA2 markedly inhibits GR transactivation ([@CIT0025]). Since we find decreased SKA2 expression in suicide, it may suggest decreased GR transactivation.

The strong interaction between GR and SKA2 suggests that abnormalities in HPA function in suicide may also be related to GR-SKA2 interaction. This assumption is further substantiated by the observation of [@CIT0010] that SKA2 genetic and epigenetic differences were associated with reduced suppression of salivary cortisol.

It has been shown that SKA2 may play a role in cell proliferation and apoptosis, as SKA2 knockdown prevented cell proliferation ([@CIT0025]). It was also found that DEX has a profound inhibitory effect on SKA2 expression, suggesting that SKA2 may play a role in antiproliferation or proapoptotic activity.

In addition to DEX, the levels of SKA2 are also regulated by Staurosporine, phorbol ester, and trichostatin A ([@CIT0025]). All of these either induce apoptosis or inhibit cell proliferation. These findings may also suggest that abnormalities of SKA2 in suicide may either cause or be related to the observed abnormalities of protein kinase C (PKC) in suicide ([@CIT0019]). Since phorbol ester binds and activates PKC and since abnormalities of PKC enzymes have been reported in the suicide brain, it is possible that underexpression of SKA2 in suicide may be related to the reported abnormalities of PKC in suicide.

It therefore appears that the main factors regulating the expression of SKA2 are GR, PKC, and DEX. Abnormal expression of these factors---PKC and GR---has been reported in the suicide brain ([@CIT0019], [@CIT0020]).

What may be the consequences of SKA2 abnormalities in suicide? Decreased SKA2 expression may cause apoptosis and/or decreased cell proliferation through its interaction with GR and/or PKC. Reported volume and structural changes in the PFC of suicidal patients ([@CIT0013]) may be a consequence of SKA2 underexpression in the suicidal brain.

Identification of biomarkers with high sensitivity and specificity for suicide and/or suicidal behavior and genes that represent a risk factor for suicide may be important in the prevention and treatment of suicidal behavior. Recent studies have suggested that some genes and their DNA methylation such as SKA2 predict suicidal behavior with high specificity in patients with suicidal behavior. Also, [@CIT0014] have identified SAT-1 gene to be specific to suicidal behavior. They also recently reported that SKA2 is indeed also a blood biomarker based on gene expression studies in blood samples of psychiatric patients and suicide completers ([@CIT0017]). Gene and protein expression studies of SKA2 show promise as a biomarker for suicide, since it appears that it is not only specific to suicide but the SKA2 decrease observed in suicide victims is independent of diagnosis and not present in nonsuicidal psychiatric patients. Studies of this gene in blood of suicidal patients are needed to further validate the usefulness of this gene as a biomarker or vulnerability marker for suicide.
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